Pioglitazone complementing insulin in diabetic kidney transplant patients not only improved glycemic control , evidenced by hemoglobin A@c , and reduced daily insulin requirement , but also decreased inflammatory markers which may have an impact on overall cardiovascular events and mortalities beyond glycemic control .